γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients
The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T‐cell‐based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy.
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2013-08, Vol.18 (8), p.e22-e23 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e23 |
|---|---|
| container_issue | 8 |
| container_start_page | e22 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 18 |
| creator | Welton, Joanne L. Martí, Salvador Mahdi, Mohammed H. Boobier, Clare Barrett‐Lee, Peter J. Eberl, Matthias |
| description | The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T‐cell‐based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy. |
| doi_str_mv | 10.1634/theoncologist.2013-0097 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3755939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1429214788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3852-9376cf7b39073e9f97e121d4fff94d3c68e3bd0e4877f8e4ee0ec2139695404e3</originalsourceid><addsrcrecordid>eNqNkUtKBDEURYMo_regGTopza86FRBBC3_Q2A5aECehOvVKI9UVTdKKM5fgXnQdLsKVmKZVdOboXch954V7EdqkZJv2uNiJN-A641p3bUPcZoTyjBAl59AyzYXKhCKX80mTgmeS5moJrYRwS0iSnC2iJcZVkTBiGfXfX9_f8BCX0LYBn3uorYl4MInGjQHbDl-5FmrvuirCx_PL0EMSNT5IM0RcVp0Bj8-raKGLYQ0tNFUbYP1rrqKLo8NheZL1B8en5X4_M7zIWaa47JlGjrgikoNqlATKaC2aplGi5qZXAB_VBEQhZVOAACBgGOWqp3JBBPBVtDfj3k1GY6hNuu2rVt95O678k3aV1X9fOnujr92D5jJPCagE2PoCeHc_gRD12AaTIqg6cJOgqWCKUSGLIlnlzGq8C8FD83OGEj3tQv_pQk-70NMu0ubG71_-7H2Hnwy7M8OjbeHpv1w9OCsHh4zxT6gjoT0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1429214788</pqid></control><display><type>article</type><title>γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients</title><source>MEDLINE</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Welton, Joanne L. ; Martí, Salvador ; Mahdi, Mohammed H. ; Boobier, Clare ; Barrett‐Lee, Peter J. ; Eberl, Matthias</creator><creatorcontrib>Welton, Joanne L. ; Martí, Salvador ; Mahdi, Mohammed H. ; Boobier, Clare ; Barrett‐Lee, Peter J. ; Eberl, Matthias</creatorcontrib><description>The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T‐cell‐based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2013-0097</identifier><identifier>PMID: 23986344</identifier><language>eng</language><publisher>Durham, NC, USA: AlphaMed Press</publisher><subject>Breast Neoplasms - drug therapy ; Chemotherapy, Adjuvant ; Diphosphonates - administration & dosage ; Female ; Humans ; Imidazoles - administration & dosage ; Letters to the Editor</subject><ispartof>The oncologist (Dayton, Ohio), 2013-08, Vol.18 (8), p.e22-e23</ispartof><rights>2013 AlphaMed Press</rights><rights>AlphaMed Press 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3852-9376cf7b39073e9f97e121d4fff94d3c68e3bd0e4877f8e4ee0ec2139695404e3</citedby><cites>FETCH-LOGICAL-c3852-9376cf7b39073e9f97e121d4fff94d3c68e3bd0e4877f8e4ee0ec2139695404e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755939/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755939/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,27924,27925,45574,45575,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23986344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Welton, Joanne L.</creatorcontrib><creatorcontrib>Martí, Salvador</creatorcontrib><creatorcontrib>Mahdi, Mohammed H.</creatorcontrib><creatorcontrib>Boobier, Clare</creatorcontrib><creatorcontrib>Barrett‐Lee, Peter J.</creatorcontrib><creatorcontrib>Eberl, Matthias</creatorcontrib><title>γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T‐cell‐based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy.</description><subject>Breast Neoplasms - drug therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Diphosphonates - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - administration & dosage</subject><subject>Letters to the Editor</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtKBDEURYMo_regGTopza86FRBBC3_Q2A5aECehOvVKI9UVTdKKM5fgXnQdLsKVmKZVdOboXch954V7EdqkZJv2uNiJN-A641p3bUPcZoTyjBAl59AyzYXKhCKX80mTgmeS5moJrYRwS0iSnC2iJcZVkTBiGfXfX9_f8BCX0LYBn3uorYl4MInGjQHbDl-5FmrvuirCx_PL0EMSNT5IM0RcVp0Bj8-raKGLYQ0tNFUbYP1rrqKLo8NheZL1B8en5X4_M7zIWaa47JlGjrgikoNqlATKaC2aplGi5qZXAB_VBEQhZVOAACBgGOWqp3JBBPBVtDfj3k1GY6hNuu2rVt95O678k3aV1X9fOnujr92D5jJPCagE2PoCeHc_gRD12AaTIqg6cJOgqWCKUSGLIlnlzGq8C8FD83OGEj3tQv_pQk-70NMu0ubG71_-7H2Hnwy7M8OjbeHpv1w9OCsHh4zxT6gjoT0</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Welton, Joanne L.</creator><creator>Martí, Salvador</creator><creator>Mahdi, Mohammed H.</creator><creator>Boobier, Clare</creator><creator>Barrett‐Lee, Peter J.</creator><creator>Eberl, Matthias</creator><general>AlphaMed Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201308</creationdate><title>γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients</title><author>Welton, Joanne L. ; Martí, Salvador ; Mahdi, Mohammed H. ; Boobier, Clare ; Barrett‐Lee, Peter J. ; Eberl, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3852-9376cf7b39073e9f97e121d4fff94d3c68e3bd0e4877f8e4ee0ec2139695404e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Breast Neoplasms - drug therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Diphosphonates - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - administration & dosage</topic><topic>Letters to the Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Welton, Joanne L.</creatorcontrib><creatorcontrib>Martí, Salvador</creatorcontrib><creatorcontrib>Mahdi, Mohammed H.</creatorcontrib><creatorcontrib>Boobier, Clare</creatorcontrib><creatorcontrib>Barrett‐Lee, Peter J.</creatorcontrib><creatorcontrib>Eberl, Matthias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Welton, Joanne L.</au><au>Martí, Salvador</au><au>Mahdi, Mohammed H.</au><au>Boobier, Clare</au><au>Barrett‐Lee, Peter J.</au><au>Eberl, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2013-08</date><risdate>2013</risdate><volume>18</volume><issue>8</issue><spage>e22</spage><epage>e23</epage><pages>e22-e23</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>The biological mechanism underlying the antitumor role of zoledronate is unclear. The analysis in this letter illustrates the diagnostic and prognostic potential of a γδ T‐cell‐based blood test and implies a link between immune responsiveness and positive outcome with zoledronate therapy.</abstract><cop>Durham, NC, USA</cop><pub>AlphaMed Press</pub><pmid>23986344</pmid><doi>10.1634/theoncologist.2013-0097</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2013-08, Vol.18 (8), p.e22-e23 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3755939 |
| source | MEDLINE; Access via Oxford University Press (Open Access Collection); Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Breast Neoplasms - drug therapy Chemotherapy, Adjuvant Diphosphonates - administration & dosage Female Humans Imidazoles - administration & dosage Letters to the Editor |
| title | γδ T Cells Predict Outcome in Zoledronate‐Treated Breast Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B3%CE%B4%20T%20Cells%20Predict%20Outcome%20in%20Zoledronate%E2%80%90Treated%20Breast%20Cancer%20Patients&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Welton,%20Joanne%20L.&rft.date=2013-08&rft.volume=18&rft.issue=8&rft.spage=e22&rft.epage=e23&rft.pages=e22-e23&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2013-0097&rft_dat=%3Cproquest_pubme%3E1429214788%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1429214788&rft_id=info:pmid/23986344&rfr_iscdi=true |